All In Biotech

Free tool

FAERS Monitor: Leqembi Iqlik

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761375 or its brand name (Leqembi Iqlik, Lecanemab-Irmb). Reports on generic versions are filed under their own applications.

Reports

17

Serious

9

53% of reports

Hospitalization

4

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • infusion related reaction6
  • headache5
  • chills4
  • dizziness3
  • hypoaesthesia3
  • muscular weakness3
  • amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits2
  • arthralgia2
  • asthenia2
  • fall2
  • myalgia2
  • pyrexia2
  • sedation2
  • tremor2
  • vomiting2

Reports by year received

View as table
YearReports
20248
20255
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,142 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits22312.8628.32,594
infusion related reactionSignal6112.058.8555
sedation294.525.7103
chillsSignal442.217.9123
muscular weaknessSignal332.711.763
hypoaesthesiaSignal324.88.947
tremor214.94.114
myalgia214.64.014
headacheSignal59.94.732
dizzinessSignal37.42.711
fall27.42.06
pyrexia27.21.95
asthenia26.61.85
arthralgia26.01.64
vomiting25.31.43

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.